Engineered-protein debate
Do now
Argue whether engineered proteins made by cloned cells should be widely used and how they should be priced.
- Hand in
- Written final stance on engineered-protein access and pricing, plus a one-sentence rebuttal to the opposing strongest argument.
- Where
- Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
You get two school days for every day you were absent, so this deadline moves with you.
has been made by engineered cells since 1982, so why does a person with diabetes in Cleveland sometimes ration a drug that costs only a few dollars to manufacture?
Argue whether engineered proteins made by cloned cells should be widely used and how they should be priced.
- • You'll be able to weigh benefits and concerns of engineered proteins.
- • You'll be able to defend a stance and respond to an objection.
- Name one medicine or medical product you think should be cheaper than it is, and say who you think decides its price.
- If a life-saving drug is easy and cheap to manufacture, list two reasons it could still end up expensive for a patient.
- 1Read the engineered- briefing in the PLTW course shell and note one benefit and one concern.
- 2Pick a role: patient, biotech firm, regulator, or ethicist, and write your opening claim.
- 3Support your claim with one piece of evidence using the term recombinant .
- 4Write a rebuttal to a competing role's strongest argument.
- 5Record the class position and your personal stance with a reason.
What did this day actually feel like?
Engineered-protein debate
ETHICS MONDAY Who owns an engineered protein, and what a patent on a therapy does to its price.
The argument for patents is that development is expensive and somebody has to fund it. The argument against is standing in a pharmacy.
AT HOME, THE NIGHT BEFORE TUE NOV 24 Plasmids and enzymes Plasmids as the vehicle, restriction enzymes as the scissors, ligase as the glue. Each enzyme cuts one specific sequence, which is what makes the cut predictable.
Turned in: notebook → Lab Notebooks folder
Fiction. There is no such student. The lessons, labs and dates are the real planned course; the student, the classmates and the conversations are invented.
The same day, drawn.
Who owns an engineered protein, and what a patent on a therapy does to its price.
Fiction. There is no such student. The lessons, labs and dates are the real planned course; the student, the classmates and the conversations are invented.
🛠 Get unstuck · pick your level
🔑 Today's words · 5
Tap a word in the lesson for a plain meaning and one example. Recycled into next week's Do-Now.
Do the work · 80-minute blockfirst 5 min = hook▸
💡 Big idea: Life-saving biotechnology raises hard questions about access because the same product must pass separate gates of price, patents, and regulation, so who controls those gates decides who the science actually helps.
- 0-8Read briefing; note one benefit and one concern
- 8-15Choose stakeholder role; draft opening claim using recombinant
- 15-30Build evidence list for your claim
- 30-50Pair debate: swap and rebut
- 50-65Class vote and discussion
- 65-80Record final stance; async post if remote
- • Engineered proteins like and growth exist because scientists inserted human genes into bacteria.
- • The science works, but who benefits and who pays are still contested questions.
- • Today you argue from four stakeholder positions before you learn how the process actually works.
- • This bioethics framing ties directly to the Biotech Research domain of the 072130 WebXam.
- • Recombinant proteins are produced by host cells carrying an inserted human gene.
- • Engineered transformed diabetes care but access remains unequal globally.
- • Pricing, intellectual property, and regulatory approval each reflect stakeholder values.
Plasmids, restriction enzymes, ligase, transformation, protein expression. · Engineered- debate
Day 1 of this lesson. Open this exact section in myPLTW (find it in Clever, Microsoft sign-in), then do the work below.
Do this: Open the engineered- debate activity in myPLTW for Lesson 4.1 Manufacturing Human Proteins, Activity 4.1.2 Protein Factories, and review the CER rubric.
Mark the debate entry complete and attach your stance note.
Unit 4 overview reserve evidence should be submitted; this debate opens the cloning unit.
Written engineered- stance and rebuttal counted as one tracker evidence item.
The official PLTW activity stays inside myPLTW. If myPLTW will not open, use F1 and E1-E3 on this page to complete today's local evidence decision, then make up the official activity when access returns. Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
Check things off as you work, then submit. This tells Mr. Mendoza how you're doing so he can help the class. It does not replace turning in your producible through the submission route shown below.
Use the code Mr. Mendoza gave you, not your name. Saved on this device.
Plasmids, restriction enzymes, ligase, transformation, protein expression. · Engineered-protein debate
Open the engineered- debate activity in myPLTW for Lesson 4.1 Manufacturing Human Proteins, Activity 4.1.2 Protein Factories, and review the CER rubric.
Unit 4 overview reserve evidence should be submitted; this debate opens the cloning unit.
This is how Mr. Mendoza sees the class keeping pace with PLTW. Be honest, it only helps if it is accurate.
🎯 Argue whether engineered proteins made by cloned cells should be widely used and how they should be priced.
- Read the engineered- briefing in the PLTW course shell and note one benefit and one concern.
- Pick a role: patient, biotech firm, regulator, or ethicist, and write your opening claim.
- Support your claim with one piece of evidence using the term recombinant .
- Write a rebuttal to a competing role's strongest argument.
- Record the class position and your personal stance with a reason.
Exit ticket: Written final stance on engineered- access and pricing, plus a one-sentence rebuttal to the opposing strongest argument.
Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not. Use the checklist just below and upload by 11:29 PM for full credit. Absent with an excused absence? You get two school days for every day you were absent, so this deadline moves with you.
| Task | Who |
|---|---|
| Read the engineered- briefing in the PLTW course shell and note one benefit and one concern. | _______ |
| Pick a role: patient, biotech firm, regulator, or ethicist, and write your opening claim. | _______ |
| Support your claim with one piece of evidence using the term recombinant . | _______ |
| Write a rebuttal to a competing role's strongest argument. | _______ |
| Record the class position and your personal stance with a reason. | _______ |
Working solo? Put your own name in "Who" for every row.
- You'll be able to weigh benefits and concerns of engineered proteins.
- You'll be able to defend a stance and respond to an objection.
- 1Do thisArgue whether engineered proteins made by cloned cells should be widely used and how they should be priced.
- 2Use this resource
- 3Submit thisExit ticket: Written final stance on engineered-protein access and pricing, plus a one-sentence rebuttal to the opposing strongest argument.
- 4Submit it here
- 1Open the drop folder.
- 2Sign in with your district Microsoft account, not a personal one.
- 3Upload the file, named Lastname_Firstname__Assignment Title.
- 4Your own upload panel says Uploaded with a green check: that is your receipt.
Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not. Genetics of Disease (Medical Interventions) › Plasmids, restriction enzymes, ligase, transformation, protein expression. › Exit ticketOpen the drop folder
Learn it · deck, reading, and vocabulary▸
The deck carries the prior idea forward, lets you inspect an analogy, maps the rule to biology, and ends with the same evidence decision and exit ticket used on this page.
Generated from this lesson's canonical data with a red-team citation check.
offers a biological alternative to donor scarcity, but readiness and risk vary by approach.
Life-saving biotechnology raises hard questions about access because the same product must pass separate gates of price, patents, and regulation, so who controls those gates decides who the science actually helps.
A library keeps a master plan protected while working copies guide production at different stations.
- Why protect the master copy?
- What information moves?
- Where can an error change the final product?
Stored information can be copied, read, and converted into a functional product.
Genes are regulated biological sequences, not conscious instructions, and one gene rarely determines a whole trait alone.
- • Master plan maps to DNA.
- • Working copy maps to RNA.
- • Production output maps to or a regulated cell function.
Driving question: has been made by engineered cells since 1982, so why does a person with diabetes in Cleveland sometimes ration a drug that costs only a few dollars to manufacture?
What you already know: offers a biological alternative to donor scarcity, but readiness and risk vary by approach.
New idea: Life-saving biotechnology raises hard questions about access because the same product must pass separate gates of price, patents, and regulation, so who controls those gates decides who the science actually helps.
Visual or model: F1. F1. A lesson illustration or teaching diagram for Engineered-protein debate. Use it with E1-E3; it is a model or context image, not experimental or patient data. What to notice: Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision.
- Observe or measure the relevant feature in Engineered- debate.
- Organize the observation with a stable evidence ID.
- Apply this rule: Stored information can be copied, read, and converted into a functional product.
- Choose the option the evidence supports and state the limit of the conclusion.
Real biomedical example: has been made by engineered cells since 1982, so why does a person with diabetes in Cleveland sometimes ration a drug that costs only a few dollars to manufacture?
What the evidence supports: E1-E3 and F1 support the daily take-home when the response meets the stated success criteria.
What it cannot prove: The package does not support claims beyond this lesson's or any real patient diagnosis.
- • : A small circular piece of DNA found in bacteria that copies itself separately from the main and is often used to carry genes in the lab.
- • : DNA made by joining genetic material from two different sources, often to insert a chosen gene into a cell so it makes a useful .
- • : An that joins two pieces of DNA together by sealing the gap in their backbone, vital in genetic engineering.
- • : The process by which a bacterial cell takes up foreign DNA, such as a , from its surroundings and begins using those new genes.
- • expression: The process of turning a gene on so its DNA instructions are used to make RNA and , deciding when and where a gene is active.
Use it now: Choose one decision option. Cite E1 and E3, then explain how the rule connects the evidence to your choice.
Go further, optional: The source links below are optional enrichment. Every fact required for today's local evidence decision appears in this lesson package.
Recombinant proteins are produced by host cells carrying an inserted human gene.
Limit: E1 supplies context or an observation; it does not by itself establish the explanation.
Life-saving biotechnology raises hard questions about access because the same product must pass separate gates of price, patents, and regulation, so who controls those gates decides who the science actually helps.
Limit: E2 is a teaching statement or comparison and must be checked against the task evidence.
You'll be able to weigh benefits and concerns of engineered proteins.
Limit: E3 supports only the result or product criterion named here; it cannot justify a broader clinical or causal claim.
PLTW-GEND-2026-11-23 · Simulated classroom evidence scenario
Your role: medical interventions team member
Decision: Your team must decide what the evidence from Engineered- debate supports before submitting the exit response named on the lesson page.
- • Select the option best supported by E1-E3.
- • Select a reasonable alternative and name the evidence it would require.
- • Delay the claim because the evidence does not distinguish the options.
Response: State one choice, cite at least two evidence IDs, explain the rule that connects them, and add one limitation. Submit it as the exit response.
Claim ceiling: The supplied lesson evidence can support an observation, pattern, classroom mechanism, or next-step decision about Engineered- debate. It cannot by itself prove causation, establish a real clinical diagnosis, or justify action outside this classroom task.
Reason for review: Your team must decide what the evidence from Engineered- debate supports before submitting the exit response named on the lesson page.
Context: A biotechnology can be scientifically brilliant and still fail people, because the same product must clear the separate hurdles of price, patent, and regulation before it reaches a patient.
- • T1: Read the engineered- briefing in the PLTW course shell and note one benefit and one concern.
- • T2: Pick a role: patient, biotech firm, regulator, or ethicist, and write your opening claim.
- • T3: Support your claim with one piece of evidence using the term recombinant .
- • T4: Write a rebuttal to a competing role's strongest argument.
- • T5: Record the class position and your personal stance with a reason.
- • E1: Recombinant proteins are produced by host cells carrying an inserted human gene.
- • E2: Life-saving biotechnology raises hard questions about access because the same product must pass separate gates of price, patents, and regulation, so who controls those gates decides who the science actually helps.
- • E3: You'll be able to weigh benefits and concerns of engineered proteins.
Measurements: Use only the measurements, units, graph, or counts supplied in today's task. No additional patient measurement is implied.
Figure finding: Teaching diagram for Engineered- debate. Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision. This is a teaching model, not patient or experimental data.
Uncertainty: This is a composite classroom scenario. Missing history, measurements, or confirmation tests remain unknown and limit the conclusion.
Mean = sum of values / number of values. Median = middle ordered value. Range = maximum - minimum.
For 2, 4, 4, and 10: mean = 20 / 4 = 5, median = 4, and range = 10 - 2 = 8.
Mean, median, and range keep the measurement unit. Order the values before finding the median.
Calculate the requested summary for today's supplied values, then write what it reveals and what it hides.
- • The solution must address the stated need in Engineered- debate.
- • The decision must be supported by E1-E3.
- • The final product must make the success criteria visible.
- • Complete the work inside the 80-minute block.
- • Use only supplied or teacher-approved materials and evidence.
- • Do not trade , accessibility, or privacy for speed.
- • and evidence quality: must pass before scoring other criteria.
- • User need and effectiveness: highest scored criterion.
- • Time, cost, and ease of use: compare only after and effectiveness pass.
Test evidence: For each option, record the E1-E3 result that supports or fails each criterion. Do not assign a score without a named observation.
- Version or option tested
- Criterion met or missed
- Evidence ID and result
- Revision made
- Reason for the revision
- Need and user
- Criteria and constraints
- Chosen option and evidence
- Test result
- Revision and reason
Students often think Students assume that if a drug is cheap to manufacture, it must be cheap to buy, so a high price must mean the science is expensive.. The trap: Price is not set by manufacturing cost alone. Patents, research recovery, insurance middlemen, and regulation all push the price, so a drug that costs pennies to make can still be sold for hundreds. Confusing cost-to-make with price-to-buy hides the real decision-makers.
Claim (final stance): A life-saving vaccine, such as a childhood measles vaccine, should be made widely available and priced so that families can actually get it, with public health programs or insurance covering the cost when a family cannot pay.\nEvidence (supporting point): Measles vaccines have been produced at large scale for decades and cut measles deaths sharply wherever coverage is high, yet outbreaks still return in communities where cost, distance, or missed doses keep vaccination rates low. This shows that a proven, protective product only prevents disease if people can actually receive it.\nReasoning: A vaccine protects not just the person who gets it but also people around them who cannot be vaccinated, because high coverage slows the spread of the disease. If price keeps coverage low, the disease keeps circulating, so the benefit of the technology is lost for the whole community, not only for the family that could not pay. That is why access and affordability, not just the existence of the vaccine, decide whether it does its job.\nRebuttal to the strongest opposing argument: The vaccine maker's strongest point is that revenue from sales pays for the research, testing, and quality control that keep the vaccine safe and available. My one-sentence rebuttal: Paying for safe production is necessary, but pricing a vaccine so high that many families skip it lets the disease spread and undermines the very protection the vaccine was made to provide, so the price should cover real costs without blocking access.
This model shows the level of evidence and organization needed to complete: Models the engineered-protein debate deliverable on a different scenario: a written final stance on the access and pricing of a life-saving vaccine, plus a one-sentence rebuttal to the opposing side's strongest argument. Use it as a format guide, not an answer key, because it argues a different case than today's prompt.
- Name the prompt or task.
- Answer it directly with the key evidence.
- Check that the response matches the requested format.
Keep the structure. Replace the question, facts, measurements, and evidence. Then recheck units, vocabulary, and whether the conclusion goes beyond the evidence.
Also due today: Post your stakeholder argument on the class site discussion, reply to one classmate who took a different position, and submit your exit ticket.
- CER:
- Claim, Evidence, Reasoning: make a claim, back it with evidence, explain your reasoning.
- SOP:
- Standard Operating Procedure, the exact steps to follow (especially in a lab).
- Tracker:
- Your PLTW progress log where you record completed evidence.
- myPLTW:
- The PLTW course site where you do the online activities. Find it in Clever with your Microsoft sign-in, right next to Schoology.
Tap the speaker to hear a term. Add two of these to your notebook glossary with a definition and an example in your own words.
Pick just 2 or 3 words from today and make them yours: write what each one means in your own words, name the context clue or evidence that helped, then give one example from what you actually did in Engineered-protein debate. Try your own words first; the glossary is there if you get stuck. This is voluntary and counts as extra credit, so keep it short.
Saved on this device. Show Mr. Mendoza or add these to your notebook glossary to claim the extra credit.
Classroom documents for this lesson are posted in Schoology. Open Clever, then Schoology, and find each one by the name shown on its card.
Use this if you were absent, got stuck, or need another pass before you submit the lesson artifact.
Placement rationale
Matched and cloning by path:Medical-Interventions/Unit-4_When-Organs-Fail/4.1_Manufacturing-Human-Proteins; keywords:, pglo. Score 142. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Use this if you were absent, got stuck, or need another pass before you submit the lesson artifact.
Placement rationale
Matched and cloning by path:Medical-Interventions/Unit-4_When-Organs-Fail/4.1_Manufacturing-Human-Proteins; keywords:, pglo. Score 138. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Use this if you were absent, got stuck, or need another pass before you submit the lesson artifact.
Placement rationale
Matched and cloning by path:Medical-Interventions/Unit-4_When-Organs-Fail/4.1_Manufacturing-Human-Proteins; keywords:, pglo. Score 138. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
How to get there: open Clever and sign in with your Microsoft (district) account. Both myPLTW and Schoology are in Clever. Do the activity in myPLTW. Turn the work in on this site or hand it to Mr. Mendoza, because that is the step that counts as submitted. Schoology only shows your report-card grade later.
Check yourself · commit, then reveal▸
Claim ceiling for this check: The supplied lesson evidence can support an observation, pattern, classroom mechanism, or next-step decision about Engineered- debate. It cannot by itself prove causation, establish a real clinical diagnosis, or justify action outside this classroom task.
A recombinant protein like insulin costs about 6 dollars to produce but sells to a patient for over 250 dollars. Name two things besides manufacturing that push the price up.
Write an answer and pick a confidence to unlock the key.
Fast retrieval with instant answers, not the commit-then-reveal check above. Try each from memory first: write what you remember about the earlier units, then check yourself here.
Go further and get help▸
What today's skills lead to. These are real health-science careers this course builds toward. Tap one to see, on the US Department of Labor's O*NET site, what the job actually involves, what it pays, and how fast it is growing.
Post a written engineered- argument from your stakeholder role in the course shell discussion, then reply to one classmate who took a different position.
Learn.Genetics: Gene Therapy and CloningThen submit your Exit ticket. Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
Class still runs. Complete the online activity above (it's self-guided). Need the concept taught without a teacher? Use this authoritative explainer:
Genetic Science Learning Center: CloningYou've passed Unit 2, so the optional extra-credit track is open. Complete reserved-unit work from home, including virtual labs, for extra credit. Each item shows its correct submission route.
Open the extra-credit track- CompleteEvery required part of the artifact is present, nothing left blank.
- AccurateThe science and the data are correct and match the evidence.
- Scientific reasoningYou explain your claim with evidence and reasoning (CER), not just an answer.
- Professional communicationClear, organized, labeled, and written the way a clinician or scientist would.
- SubmittedTurned in the right way, on the class site or handed to Mr. Mendoza in class, and confirmed. Not in Schoology: that is where the report-card grade appears later.